Frédéric Bigot
Impact in
-
- Cancer Immunotherapy and Biomarkers
- Inflammatory Biomarkers in Disease Prognosis
- Lung Cancer Research Studies
-
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
Papers in
- Oncology 24
- Cancer Immunotherapy and Biomarkers 9
- COVID-19 and healthcare impacts 6
-
- Lung Cancer Treatments and Mutations 6
- Co-authors
- Christophe Massard (5 shared papers)Jean‐Marie Michot (3 shared papers)Antoine Hollebecque (3 shared papers)Eduardo Castañón (2 shared papers)Sophie Postel‐Vinay (3 shared papers)Aurélien Marabelle (3 shared papers)Capucine Baldini (2 shared papers)Sandrine Aspeslagh (3 shared papers)
In The Last Decade
Frédéric Bigot
31 papers receiving 349 citations
Peers
Comparison fields: 5 of 65
- Oncology 220
- Pulmonary and Respiratory Medicine 140
- Cancer Research 64
- Surgery 84
- Orthopedics and Sports Medicine 15
Countries citing papers authored by Frédéric Bigot
This map shows the geographic impact of Frédéric Bigot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Bigot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Bigot more than expected).
Fields of papers citing papers by Frédéric Bigot
This network shows the impact of papers produced by Frédéric Bigot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Bigot. The network helps show where Frédéric Bigot may publish in the future.
Co-authors
The 25 scholars most cited alongside Frédéric Bigot, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 145 | |
| 2 | 2011 | 47 | |
| 3 | 2013 | 46 | |
| 4 | 2016 | 20 | |
| 5 | 2023 | 11 | |
| 6 | 2018 | 11 | |
| 7 | 2023 | 8 | |
| 8 | 2017 | 8 | |
| 9 | 2020 | 8 | |
| 10 | 2021 | 7 | |
| 11 | 2021 | 6 | |
| 12 | 2023 | 5 | |
| 13 | 2021 | 5 | |
| 14 | 2023 | 3 | |
| 15 | 2024 | 3 | |
| 16 | 2022 | 3 | |
| 17 | 2023 | 2 | |
| 18 | 2022 | 2 | |
| 19 | 2016 | 2 | |
| 20 | 2023 | 2 |
About Frédéric Bigot
Frédéric Bigot is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Surgery and Molecular Biology, having authored 33 papers that have together received 356 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Cancer Genomics and Diagnostics (6 papers), Lung Cancer Treatments and Mutations (6 papers), COVID-19 and healthcare impacts (6 papers), Endometrial and Cervical Cancer Treatments (3 papers), Bladder and Urothelial Cancer Treatments (3 papers), COVID-19 Clinical Research Studies (3 papers) and Colorectal and Anal Carcinomas (3 papers). The work is most often cited by research in Oncology (220 citations), Pulmonary and Respiratory Medicine (140 citations), Cancer Research (64 citations), Surgery (84 citations) and Orthopedics and Sports Medicine (15 citations). Frédéric Bigot has collaborated with scholars based in France, Italy and Spain. Frequent co-authors include Christophe Massard, Jean‐Marie Michot, Antoine Hollebecque, Eduardo Castañón, Sophie Postel‐Vinay, Aurélien Marabelle, Capucine Baldini, Sandrine Aspeslagh, Andréa Varga and Eric Angevin. Their work appears in journals such as Annals of Oncology, Cancers, Journal of Clinical Oncology, ESMO Open and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.